Announce top line data from the pivotal GEM-3 study for B-VEC

Deadline passed; outcome being checked

What the company said

“2H21 B-VEC for DEB Announce top line data from the pivotal GEM-3 study”

SourceKrystal Biotech, Inc. Form 8-K press release, 2021-01-07
FilingSEC filing index
Deadline as stated2H21
Deadline used31 Dec 2021, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-KRYS-021269
Cite as https://keptindex.org/c/KI-C-2021-KRYS-021269/ — this address never changes.

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Version 1 · original · stated 7 Jan 2021

Deadline 31 Dec 2021 (“2H21”)
Version 2 · stated 1 Mar 2021

Deadline 31 Dec 2021 (“in 4Q21”) · wording expected

“Top line data is anticipated in 4Q21 followed by BLA filing shortly after”
Source for this version

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Krystal Biotech, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.